Trial Profile
A retrospective, multicentre cohort study of fixed dose Lamivudine/abacavir (ABC/3TC) plus Rilpivirine in HIV infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2016
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SIMRIKI
- 01 Mar 2016 New trial record